{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:07:00Z","timestamp":1787771220524,"version":"build-2784847793"},"update-to":[{"DOI":"10.1371\/journal.pgen.1007679","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000}}],"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T00:00:00Z","timestamp":1537920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA101942"],"award-info":[{"award-number":["CA101942"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Loker Pinard"},{"name":"Michael Brigham Funds"}],"content-domain":{"domain":["www.plosgenetics.org"],"crossmark-restriction":false},"short-container-title":["PLoS Genet"],"DOI":"10.1371\/journal.pgen.1007679","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T17:36:20Z","timestamp":1537983380000},"page":"e1007679","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgen.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma"],"prefix":"10.1371","volume":"14","author":[{"given":"Lana","family":"Hamieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":true,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Og\u00f3rek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damir","family":"Khabibullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rosebrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Livitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9627-4078","authenticated-orcid":true,"given":"Jean-Christophe","family":"Pignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Signoretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5668-5219","authenticated-orcid":true,"given":"David J.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,9,26]]},"reference":[{"issue":"4","key":"ref1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic Therapy for Metastatic Renal-Cell Carcinoma","volume":"376","author":"TK Choueiri","year":"2017","journal-title":"N Engl J Med"},{"issue":"9637","key":"ref2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"RJ Motzer","year":"2008","journal-title":"Lancet"},{"issue":"22","key":"ref3","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"G Hudes","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.trecan.2016.03.008","article-title":"Emerging role of mTOR in the response to cancer therapeutics","volume":"2","author":"E Ilagan","year":"2016","journal-title":"Trends Cancer"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"J Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"ref6","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"RJ Motzer","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"168","author":"RA Saxton","year":"2017","journal-title":"Cell"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ceb.2017.02.012","article-title":"mTORC1 signaling and the metabolic control of cell growth","volume":"45","author":"I Ben-Sahra","year":"2017","journal-title":"Curr Opin Cell Biol"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1056\/NEJMcibr1406613","article-title":"Molecular basis of giant cells in tuberous sclerosis complex","volume":"371","author":"DJ Kwiatkowski","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/2159-8290.CD-13-0929","article-title":"A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity","volume":"4","author":"BC Grabiner","year":"2014","journal-title":"Cancer discovery"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1172\/JCI86120","article-title":"Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin","volume":"126","author":"J Xu","year":"2016","journal-title":"J Clin Invest"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.celrep.2016.02.024","article-title":"Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma","volume":"14","author":"F Chen","year":"2016","journal-title":"Cell reports"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/onc.2016.246","article-title":"Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth","volume":"36","author":"Y Wang","year":"2017","journal-title":"Oncogene"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-15-2631","article-title":"Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma","volume":"22","author":"DJ Kwiatkowski","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2016.10.007","article-title":"Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma","volume":"71","author":"JJ Hsieh","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nbt.2203","article-title":"Absolute quantification of somatic DNA alterations in human cancer","volume":"30","author":"SL Carter","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/ng.3602","article-title":"The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis","volume":"48","author":"WJ Gibson","year":"2016","journal-title":"Nat Genet"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"DA Landau","year":"2013","journal-title":"Cell"},{"issue":"7456","key":"ref19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"issue":"6733","key":"ref20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"PH Maxwell","year":"1999","journal-title":"Nature"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ijc.27822","article-title":"Loss of PBRM1 expression is associated with renal cell carcinoma progression","volume":"132","author":"R Pawlowski","year":"2013","journal-title":"Int J Cancer"},{"issue":"7331","key":"ref22","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature09639","article-title":"Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma","volume":"469","author":"I Varela","year":"2011","journal-title":"Nature"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1073\/pnas.1619726114","article-title":"Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-\/- clear cell renal carcinoma","volume":"114","author":"W Gao","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"43","key":"ref24","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"A Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"M Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"ref26","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.eururo.2016.11.018","article-title":"Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness","volume":"71","author":"DJ Serie","year":"2017","journal-title":"Eur Urol"},{"issue":"12","key":"ref27","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92688","article-title":"Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma","volume":"2","author":"J Casuscelli","year":"2017","journal-title":"JCI Insight"},{"issue":"7606","key":"ref28","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nature17963","article-title":"Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor","volume":"534","author":"VS Rodrik-Outmezguine","year":"2016","journal-title":"Nature"},{"issue":"15","key":"ref29","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1056\/NEJMoa1403352","article-title":"Response and acquired resistance to everolimus in anaplastic thyroid cancer","volume":"371","author":"N Wagle","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-13-0353","article-title":"Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib","volume":"4","author":"N Wagle","year":"2014","journal-title":"Cancer discovery"},{"issue":"6377","key":"ref31","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"D Miao","year":"2018","journal-title":"Science"}],"updated-by":[{"DOI":"10.1371\/journal.pgen.1007679","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T00:00:00Z","timestamp":1539216000000}}],"container-title":["PLOS Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pgen.1007679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T10:11:15Z","timestamp":1589019075000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgen.1007679"}},"subtitle":[],"editor":[{"given":"David","family":"Nanus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,9,26]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgen.1007679","relation":{"new_version":[{"id-type":"doi","id":"10.1371\/journal.pgen.1007679","asserted-by":"object"}]},"ISSN":["1553-7404"],"issn-type":[{"value":"1553-7404","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,26]]}}}